PubRank

Emanuel F Petricoin

Author PubWeight™ 193.67‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003 15.43
2 Human Proteinpedia enables sharing of human protein data. Nat Biotechnol 2008 4.21
3 Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 2005 4.18
4 Laser-capture microdissection. Nat Protoc 2006 3.80
5 Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003 3.61
6 Importance of communication between producers and consumers of publicly available experimental data. J Natl Cancer Inst 2005 2.63
7 Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J Urol 2009 2.54
8 Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest 2005 2.38
9 Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 2003 2.32
10 Breast cancer growth prevention by statins. Cancer Res 2006 2.09
11 An investigation into the human serum "interactome". Electrophoresis 2004 1.93
12 A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 2008 1.88
13 A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin Chem 2007 1.87
14 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics 2002 1.85
15 Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin Cancer Res 2012 1.74
16 Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat Rev Drug Discov 2007 1.73
17 Mass spectrometry-based diagnostics: the upcoming revolution in disease detection. Clin Chem 2003 1.69
18 Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics 2003 1.66
19 Proteomics of human breast ductal carcinoma in situ. Cancer Res 2002 1.62
20 Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano Lett 2007 1.58
21 A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology 2007 1.54
22 Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood 2007 1.52
23 Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 2006 1.52
24 Asymmetric cancer cell division regulated by AKT. Proc Natl Acad Sci U S A 2011 1.52
25 Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications. Proteomics 2003 1.50
26 Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics 2008 1.44
27 Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 2003 1.44
28 Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem 2005 1.43
29 Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res 2008 1.42
30 Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic 2002 1.42
31 Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 2003 1.40
32 Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. PLoS One 2010 1.35
33 Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics 2003 1.33
34 Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med 2009 1.31
35 Analysis of mass spectral serum profiles for biomarker selection. Bioinformatics 2005 1.30
36 Secreted neutral metalloproteases of Bacillus anthracis as candidate pathogenic factors. J Biol Chem 2006 1.28
37 Biomarker amplification by serum carrier protein binding. Dis Markers 2004 1.26
38 An initial characterization of the serum phosphoproteome. J Proteome Res 2009 1.26
39 Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 2010 1.26
40 Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. J Immunother 2005 1.25
41 Clinical proteomics and biomarker discovery. Ann N Y Acad Sci 2004 1.24
42 Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers. PLoS One 2009 1.23
43 Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays. Nat Clin Pract Oncol 2006 1.23
44 Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J Urol 2004 1.20
45 The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia. Haematologica 2012 1.18
46 Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693. BMC Genomics 2010 1.14
47 Functional protein pathway activation mapping of the progression of normal skin to squamous cell carcinoma. Cancer Prev Res (Phila) 2012 1.14
48 Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. Adv Exp Med Biol 2003 1.14
49 Multifunctional core-shell nanoparticles: discovery of previously invisible biomarkers. J Am Chem Soc 2011 1.11
50 Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer. Ann Surg Oncol 2007 1.10
51 Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer. Mol Cancer Ther 2011 1.09
52 Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. Lab Invest 2010 1.09
53 Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Rev Mol Diagn 2007 1.09
54 A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Res Treat 2014 1.08
55 The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer 2007 1.08
56 CSF proteome: a protein repository for potential biomarker identification. Expert Rev Proteomics 2005 1.08
57 Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability. Proteomics Clin Appl 2009 1.08
58 Concentration and Preservation of Very Low Abundance Biomarkers in Urine, such as Human Growth Hormone (hGH), by Cibacron Blue F3G-A Loaded Hydrogel Particles. Nano Res 2008 1.07
59 Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. J Proteome Res 2011 1.07
60 Pathology of the future: molecular profiling for targeted therapy. Cancer Invest 2005 1.06
61 Regulatory approval pathways for molecular diagnostic technology. Methods Mol Biol 2012 1.06
62 Drosophila screening model for metastasis: Semaphorin 5c is required for l(2)gl cancer phenotype. Proc Natl Acad Sci U S A 2003 1.06
63 Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy. Hum Genomics 2004 1.05
64 The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer. Clin Cancer Res 2003 1.04
65 Protein microarray detection strategies: focus on direct detection technologies. J Immunol Methods 2004 1.03
66 Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev Mol Diagn 2002 1.03
67 One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS One 2011 1.03
68 FINDbase: a worldwide database for genetic variation allele frequencies updated. Nucleic Acids Res 2010 1.00
69 A new scientific journal linked to a genetic database: towards a novel publication modality. Hum Genomics Proteomics 2008 1.00
70 Mitochondrial proteome: cancer-altered metabolism associated with cytochrome c oxidase subunit level variation. Proteomics 2004 1.00
71 Proteomic analysis of lymph. Proteomics 2004 0.99
72 Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells. Mol Cancer Res 2007 0.99
73 A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. Arthritis Rheum 2005 0.98
74 Reverse-phase phosphoproteome analysis of signaling pathways induced by Rift valley fever virus in human small airway epithelial cells. PLoS One 2010 0.98
75 Nanoporous surfaces as harvesting agents for mass spectrometric analysis of peptides in human plasma. J Proteome Res 2006 0.98
76 Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response. Arch Ophthalmol 2009 0.98
77 Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors. Mol Cancer Ther 2011 0.96
78 Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol 2011 0.95
79 Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy. Biosci Rep 2005 0.95
80 Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation. J Proteome Res 2011 0.94
81 Nanoparticle technology: Addressing the fundamental roadblocks to protein biomarker discovery. J Mater Chem 2009 0.94
82 Serum proteomics in cancer diagnosis and management. Annu Rev Med 2004 0.93
83 The use of hydrogel microparticles to sequester and concentrate bacterial antigens in a urine test for Lyme disease. Biomaterials 2010 0.93
84 Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology. AAPS J 2010 0.93
85 Biomarkers of ovarian tumours. Eur J Cancer 2004 0.92
86 Mass spectrometry analysis of the post-translational modifications of alpha-enolase from pancreatic ductal adenocarcinoma cells. J Proteome Res 2010 0.92
87 Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer. Neoplasia 2009 0.92
88 The role of proteomics in prostate cancer research: biomarker discovery and validation. Clin Biochem 2012 0.92
89 Proteomic analysis of human prostate cancer. Mol Carcinog 2002 0.91
90 Proteomic analysis of eccrine sweat: implications for the discovery of schizophrenia biomarker proteins. J Proteome Res 2012 0.91
91 Reverse phase protein microarrays for monitoring biological responses. Methods Mol Biol 2007 0.91
92 Proteomic analysis of pancreatic ductal adenocarcinoma cells reveals metabolic alterations. J Proteome Res 2011 0.91
93 Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy. Ann Surg 2007 0.90
94 Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. J Proteome Res 2009 0.90
95 Selective binding and enrichment for low-molecular weight biomarker molecules in human plasma after exposure to nanoporous silica particles. Proteomics 2006 0.90
96 Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients. PLoS One 2009 0.90
97 A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum. Exp Dermatol 2011 0.89
98 Systems analysis of the NCI-60 cancer cell lines by alignment of protein pathway activation modules with "-OMIC" data fields and therapeutic response signatures. Mol Cancer Res 2013 0.89
99 Quantitative cell signalling analysis reveals down-regulation of MAPK pathway activation in colorectal cancer. J Pathol 2009 0.89
100 Using decision forest to classify prostate cancer samples on the basis of SELDI-TOF MS data: assessing chance correlation and prediction confidence. Environ Health Perspect 2004 0.89
101 Reverse-phase protein microarrays. Methods Mol Biol 2012 0.89
102 Reverse-phase protein microarrays for theranostics and patient tailored therapy. Methods Mol Biol 2009 0.88
103 Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations. Cancer Res 2013 0.88
104 Preclinical magnetic resonance imaging and systems biology in cancer research: current applications and challenges. Am J Pathol 2012 0.88
105 Elevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors. Clin Cancer Res 2013 0.88
106 Physicochemically modified silicon as a substrate for protein microarrays. Biomaterials 2006 0.88
107 A method for the selective isolation and enrichment of carrier protein-bound low-molecular weight proteins and peptides in the blood. Proteomics Clin Appl 2007 0.87
108 Nanoparticle technology: amplifying the effective sensitivity of biomarker detection to create a urine test for hGH. Drug Test Anal 2009 0.86
109 Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines. Int J Cancer 2012 0.86
110 Putting the "bio" back into biomarkers: orienting proteomic discovery toward biology and away from the measurement platform. Clin Chem 2008 0.86
111 Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data. Cancer Epidemiol Biomarkers Prev 2011 0.86
112 Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. Breast Cancer Res Treat 2011 0.86
113 Discovery of mouse spleen signaling responses to anthrax using label-free quantitative phosphoproteomics via mass spectrometry. Mol Cell Proteomics 2010 0.86
114 Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy. Cancer Genomics Proteomics 2007 0.85
115 Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis. Cancer Res 2005 0.85
116 -Omics and cancer biomarkers: link to the biological truth or bear the consequences. Cancer Epidemiol Biomarkers Prev 2012 0.85
117 Use of proteomic analysis to monitor responses to biological therapies. Expert Opin Biol Ther 2004 0.85
118 Protein quantification by mass spectrometry: is it ready for prime time? Clin Chem 2009 0.84
119 Application of physicochemically modified silicon substrates as reverse-phase protein microarrays. J Proteome Res 2009 0.84
120 Mass spectrometry-based characterization of the vitreous phosphoproteome. Proteomics Clin Appl 2010 0.84
121 Molecular network analysis using reverse phase protein microarrays for patient tailored therapy. Adv Exp Med Biol 2008 0.83
122 Mass spectrometry-based protein biomarker discovery: solving the remaining challenges to reach the promise of clinical benefit. Clin Chem 2010 0.83
123 The amplified peptidome: the new treasure chest of candidate biomarkers. Curr Opin Chem Biol 2006 0.83
124 Reverse phase protein microarrays for theranostics and patient-tailored therapy. Methods Mol Biol 2008 0.83
125 Preparation and use of reverse protein microarrays. Curr Protoc Protein Sci 2014 0.82
126 Reverse phase protein microarrays and their utility in drug development. Methods Mol Biol 2013 0.82
127 Molecular diagnostics: an FDA perspective. Expert Rev Mol Diagn 2003 0.82
128 Reverse-phase protein microarrays for tissue-based analysis. Curr Opin Mol Ther 2005 0.81
129 The spectra count label-free quantitation in cancer proteomics. Cancer Genomics Proteomics 2012 0.81
130 Stratification of clear cell renal cell carcinoma by signaling pathway analysis. Expert Rev Proteomics 2014 0.81
131 Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy. Crit Rev Clin Lab Sci 2010 0.80
132 MS analysis reveals O-methylation of L-lactate dehydrogenase from pancreatic ductal adenocarcinoma cells. Electrophoresis 2012 0.80
133 Reverse phase protein microarrays for clinical applications. Methods Mol Biol 2011 0.80
134 Novel approaches to visualization and data mining reveals diagnostic information in the low amplitude region of serum mass spectra from ovarian cancer patients. Dis Markers 2004 0.80
135 Synthesis and characterization of hydrogel particles containing Cibacron Blue F3G-A. Colloids Surf A Physicochem Eng Asp 2010 0.80
136 Cancer metabolism: what we can learn from proteomic analysis by mass spectrometry. Cancer Genomics Proteomics 2012 0.80
137 Transcriptomic and phospho-proteomic analyzes of erythroblasts expanded in vitro from normal donors and from patients with polycythemia vera. Am J Hematol 2013 0.79
138 Opportunities for nanotechnology-based innovation in tissue proteomics. Biomed Microdevices 2004 0.79
139 Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research. Clin Adv Hematol Oncol 2003 0.79
140 A novel function of RNAs arising from the long terminal repeat of human endogenous retrovirus 9 in cell cycle arrest. J Virol 2012 0.79
141 Use of proteomic patterns to screen for gastrointestinal malignancies. Surgery 2004 0.78
142 STUDENTJAMA. Molecular technologies for personalized cancer management. JAMA 2004 0.78
143 Trapping radioactive carbon dioxide during cellular metabolic assays under standard culture conditions: description of a unique gas-capturing device. J Biochem Biophys Methods 2004 0.78
144 Mass spectrometric analysis reveals O-methylation of pyruvate kinase from pancreatic cancer cells. Anal Bioanal Chem 2013 0.78
145 Blasting into the microworld of tissue proteomics: a new window on cancer. Clin Cancer Res 2004 0.78
146 Clinical proteomics for cancer biomarker discovery and therapeutic targeting. Technol Cancer Res Treat 2002 0.78
147 Reverse phase protein microarrays: fluorometric and colorimetric detection. Methods Mol Biol 2011 0.78
148 Profiling the activity of G proteins in patient-derived tissues by rapid affinity-capture of signal transduction proteins (GRASP). Proteomics 2004 0.77
149 Mass spectrometry-based biomarker discovery. Methods Mol Biol 2012 0.77
150 Nanoparticles: potential biomarker harvesters. Curr Opin Chem Biol 2006 0.77
151 Clinical application of proteomics in ovarian cancer prevention and treatment. Mol Diagn Ther 2009 0.77
152 General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer. Gynecol Oncol 2003 0.76
153 Molecular diagnostics. Hematology Am Soc Hematol Educ Program 2003 0.76
154 The promise of proteomics. Clin Adv Hematol Oncol 2003 0.76
155 Application of Analyte Harvesting Nanoparticle Technology to the Measurement of Urinary HGH in Healthy Individuals. J Sports Med Doping Stud 2012 0.76
156 Proteomic technologies to study diseases of the lymphatic vascular system. Ann N Y Acad Sci 2002 0.75
157 Combining markers with and without the limit of detection. Stat Med 2013 0.75
158 Proteomics Discovery of Disease Biomarkers. Biomark Insights 2008 0.75
159 Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria. Cell Chem Biol 2017 0.75
160 Quantum dots for biomedical applications. Expert Opin Med Diagn 2008 0.75
161 Dilution of protein gel stain results in retention of staining capacity. Biotechniques 2003 0.75